{"id":"W4407678056","doi":"10.1200/jco.2025.43.5_suppl.tps279","title":"Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Prostate cancer; Androgen receptor; Placebo; Oncology; Internal medicine; Hormone receptor; Cohort; Cancer; Androgen; Enzalutamide; Receptor; Prostate; Cancer research; Hormone; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003297567,0.003420277,0.004529462,0.000642439,0.000912962,0.001564376,0.001733328,0.003003959,0.01158772],"category_scores_gemma":[0.002529981,0.001678186,0.002535744,0.0006422786,0.002188224,0.002064734,0.0007455986,0.005116209,0.002378094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001048752,"about_ca_system_score_gemma":0.002320047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001260098,"about_ca_topic_score_gemma":0.003289713,"domain_scores_codex":[0.9988851,0.000524178,0.00005114626,0.0002688213,0.00008778057,0.0001829567],"domain_scores_gemma":[0.9983395,0.0002806531,0.0003589974,0.0001853787,0.0001607523,0.0006746974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9738573,0.01731151,0.0006202734,0.0002942062,0.0007177218,0.00002739627,0.00004647082,0.000157474,0.001855524,0.00005580819,0.0007731967,0.004283233],"study_design_scores_gemma":[0.9467376,0.05119857,0.001166503,0.00001095057,0.0002031327,0.00001616399,0.00001337448,0.0001291406,0.0001416056,0.00006381823,0.0003083002,0.00001087861],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709867,0.003555927,0.001476907,0.001233478,0.00111071,0.01422087,0.003832224,0.0003765015,0.003206703],"genre_scores_gemma":[0.9605844,0.002583763,0.004232232,0.003533101,0.00113054,0.01723935,0.003906835,0.00009234466,0.006697404],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01158772,"threshold_uncertainty_score":0.03876477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03859430156463788,"score_gpt":0.4102411276178701,"score_spread":0.3716468260532322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}